Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth

  • Jiménez Pérez, Raúl
  • Martín-Cortázar, Carla
  • Kourani, Omar
  • Chiodo, Yuri
  • Córdoba, Raúl
  • Domínguez-Franjo, María Purificación
  • Redondo, Juan Miguel
  • Iglesias, Teresa
  • Campanero, Miguel R.
Tumor formation involves the acquisition of numerous capacities along the progression from a normal cell into a malignant cell, including limitless proliferation (immortalization) and anchorage-independent growth, a capacity that correlates extremely well with tumorigenesis. Great efforts have been made to uncover genes involved in tumor formation, but most genes identified participate in processes related to cell proliferation. Accordingly, therapies targeting these genes also affect the proliferation of normal cells. To identify potential targets for therapeutic intervention more specific to tumor cells, we looked for genes implicated in the acquisition of anchorage-independent growth and in vivo tumorigenesis capacity. A transcriptomic analysis identified CDCA7 as a candidate gene. Indeed, CDCA7 protein was upregulated in Burkitt's lymphoma cell lines and human tumor biopsy specimens relative to control cell lines and tissues, respectively. CDCA7 levels were also markedly elevated in numerous T and B-lymphoid tumor cell lines. While CDCA7 was not required for anchorage-dependent growth of normal fibroblasts or non-malignant lymphocytes, it was essential but not sufficient for anchorage-independent growth of lymphoid tumor cells and for lymphomagenesis. These data suggest that therapies aimed at inhibiting CDCA7 expression or function might significantly decrease the growth of lymphoid tumors., This work was supported by the Spanish Ministerio de Economía, Industria y Competitividad (MEIC) grants to MRC. (SAF2013-45258P and SAF2017-88881-R) and TIV. (SAF2014-52737P); and by Instituto de Salud Carlos III (CIBERNED) to TIV. The cost of this publication has been paid in part with FEDER funds. OK holds an FPI fellowship from MEIC (BES-2014-069236). The CNIC is supported by the Ministerio de Ciencia, Investigación y Universidades and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glutathione overproduction mediates lymphoma initiating cells survival and has a sex-dependent effect on lymphomagenesis

  • Hernández Alcántara, Alberto
  • Kourani, Omar
  • Marcos-Jiménez, Ana
  • Martínez-Núñez, Patricia
  • Herranz-Martín, E.
  • Fuentes, Patricia
  • Toribio, María L.
  • Muñoz-Calleja, Cecilia
  • Iglesias, Teresa
  • Campanero, Miguel R.
Lymphoid tumor patients often exhibit resistance to standard therapies or experience relapse post-remission. Relapse is driven by Tumor Initiating Cells (TICs), a subset of tumor cells capable of regrowing the tumor and highly resistant to therapy. Growing cells in 3D gels is a method to discern tumorigenic cells because it strongly correlates with tumorigenicity. The finding that TICs, rather than differentiated tumor cells, grow in 3D gels offers a unique opportunity to unveil TIC-specific signaling pathways and therapeutic targets common to various cancer types. Here, we show that culturing lymphoid cells in 3D gels triggers reactive oxygen species (ROS) production, leading to non-tumor lymphoid cell death while enabling the survival and proliferation of a subset of lymphoma/leukemia cells, TICs or TIC-like cells. Treatment with the antioxidant N-acetylcysteine inhibits this lethality and promotes the growth of primary non-tumor lymphoid cells in 3D gels. A subset of lymphoma cells, characterized by an increased abundance of the antioxidant glutathione, escape ROS-induced lethality, a response not seen in non-tumor cells. Reducing glutathione production in lymphoma cells, either through pharmacological inhibition of glutamate cysteine ligase (GCL), the enzyme catalyzing the rate-limiting step in glutathione biosynthesis, or via knockdown of GCLC, the GCL catalytic subunit, sharply decreased cell growth in 3D gels and xenografts. Tumor cells from B-cell lymphoma/leukemia patients and λ-MYC mice, a B-cell lymphoma mouse model, overproduce glutathione. Importantly, pharmacological GCL inhibition hindered lymphoma growth in female λ-MYC mice, suggesting that this treatment holds promise as a therapeutic strategy for female lymphoma/leukemia patients., The CBM is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, and is a Severo Ochoa Center of Excellence (grant CEX2021-001154-S) funded by MICIN/AEI/10.13039/501100011033. This work was supported by Fundación de la Asociación Española contra el Cáncer (AECC) grant PROYE20060CAMP to M.R.C., grant PID2022-138880OB-I00 funded by MCIN /AEI /10.13039/501100011033 / FEDER, UE to M.L.T., grant PID2020-115218RB-I00 funded by MCIN/AEI/10.13039/501100011033 to T.I., and Instituto de Salud Carlos III (CIBERNED) to T.I. O.K. held an FPI fellowship from the Spanish Ministerio de Educacion y Ciencia (BES-2014-069236)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001154-S)., Peer reviewed